Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Fourth-Quarter and Full-Year 2021 Financial Results on February 14, 2022

Omnicell to Release Fourth-Quarter and Full-Year 2021 Financial Results on February 14, 2022

Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.

Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout

Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.

Here's Why You Should Add Omnicell (OMCL) Stock for Now

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Acquires MarkeTouch Media

Omnicell Acquires MarkeTouch Media

Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.

Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of ReCept

Omnicell Completes Acquisition of ReCept

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Omnicell (OMCL)

Cerner

CERN vs. OMCL: Which Stock Is the Better Value Option?

CERN vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell (OMCL) is an Incredible Growth Stock: 3 Reasons Why

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Omnicell (OMCL) Down 1% Since Last Earnings Report: Can It Rebound?

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire ReCept

Omnicell to Acquire ReCept

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences

Omnicell to Present at Upcoming Investor Conferences

3 Reasons Growth Investors Will Love Omnicell (OMCL)

Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.

Here's Why You Should Add Omnicell (OMCL) To Your Portfolio

NextGen Healthcare Inc

NXGN vs. OMCL: Which Stock Is the Better Value Option?

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

MOUNTAIN VIEW, Calif. & LAKE ZURICH, Ill.--(BUSINESS WIRE)--Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals

Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals

Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.

Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up

Omnicell, Inc.'s (OMCL) CEO Randall Lipps on Q3 2021 Results - Earnings Call Transcript

NXGN or OMCL: Which Is the Better Value Stock Right Now?

Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates

Omnicell (NASDAQ:OMCL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: Omnicell Q3 Earnings

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Company's Central Pharmacy Dispensing Service (“CPDS”) in an effort to enhance patient safety, improve operational efficiency, and optimize inventory management for its central pharmacy operations. The Veterans Health Administra

Tucson VA Medical Center Selects Omnicell's Central Pharmacy Dispensing Service to Enhance Medication Inventory Management

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2021. GAAP Results Total GAAP revenues for the third quarter of 2021 were $296.4 million, up $82.7 million, or 38.7%, from the third quarter of 2020. The increase in GAAP revenues reflec

News for Omnicell Stock (OMCL)